InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,489.86
(
0.45%
)
Post# of 252201
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: bellweather1 post# 178022

Friday, 05/16/2014 1:06:59 PM

Friday, May 16, 2014 1:06:59 PM

Post# of 252201
We agree, since combos have broken the 80% ORR barrier with acceptable safety there's no going back to monotherapy. I'm not in this stock, but I had the same optimism with IPI-145 based on presentations like below, but ibrutinib/idelalisib changed everything, IPI-145 immediately became past tense. I hear you on 1202's safety but without an ORR on the table I remain unconvinced.

http://web.oncoletter.ch/files/cto_layout/Kongressdateien/WCLC13/CLLFlinn.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up